MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

191.72
-7.72
-3.87%
After Hours: 191.50 -0.22 -0.11% 19:46 11/11 EST
OPEN
198.89
PREV CLOSE
199.44
HIGH
199.17
LOW
191.67
VOLUME
376.30K
TURNOVER
--
52 WEEK HIGH
200.00
52 WEEK LOW
108.00
MARKET CAP
11.57B
P/E (TTM)
-17.0218
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BGNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BGNE News

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE
  • ACCESSWIRE.7h ago
  • Why Amgen's Stock Soared in October
  • MotleyFool.com.16h ago
  • BeiGene Q3 2019 Earnings Preview
  • seekingalpha.1d ago
  • ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE
  • GlobeNewswire.1d ago

More

Industry

Biotechnology & Medical Research
-0.40%
Pharmaceuticals & Medical Research
-0.41%

Hot Stocks

Name
Price
%Change

About BGNE

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More

Webull offers Beigene Ltd (ADR) (BGNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.